Phaseline

Companies › Camurus

Camurus: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CAM2029
Somatostatin receptor agonist (octreotide subcutaneous depot)
SSTR2Phase 3Gastro-enteropancreatic Neuroendocrine Tumor; Polycystic Liver DiseaseNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05050942CAM2029Phase 3Gastro-enteropancreatic Neuroendocrine TumorGastroenterologyNov 2026
NCT05281328CAM2029Phase 2Polycystic Liver DiseaseGastroenterologyAug 2027

Targets

SSTR2 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio ITM Solucin Nanjing Chia-tai Tianqing Pharmaceutical Orano Med Jiangsu HengRui Medicine Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology

Companies built like this

Advanced Accelerator Applications VectivBio Pharmicell Akero Therapeutics LyGenesis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.